The most recent consensus algorithm released by the ADA/EASD lists GLP-1 analogues as a treatment option for consideration as a Tier 2 agent, or less well-validated therapy, in T2DM patients ( FIGURE 1 )
They exhibit anti-inflammatory and chondroprotective effects by suppressing nuclear factor kappa B (NF-B), protein kinase A (PKA)/cAMP Response Element-Binding protein (CREB), and MAPK pathways, reducing cytokine synthesis, oxidative stress, and endoplasmic reticulum stress
Back Mojsov, Svetlana, interviewed by Lara Marks, 10 Jan 2025, unpublished transcript
The guide lets you know what to expect and how to handle situations that may arise during treatment
Whether that's worth the wait, the cost, and the uncertainty of using an unapproved drug depends on your situation
The reason is entirely about gastrointestinal tolerability nausea, diarrhea, and vomiting were clearly dose-dependent and concentrated in the weeks right after each step-up
